Artemin, a Member of the Glial Cell Line-derived Neurotrophic Factor Family of Ligands, Is HER2-regulated and Mediates Acquired Trastuzumab Resistance by Promoting Cancer Stem Cell-like Behavior in Mammary Carcinoma Cells

Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24

(2014) Vijay Pandey et al.   Translational Oncology

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab

(2013) W. J. Gradishar   ANNALS OF ONCOLOGY

Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, proteins binding ARTEMIN, in mammary carcinoma

(2013) Zheng-Sheng Wu et al.   BMC CANCER

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

(2013) S. Ithimakin et al.   CANCER RESEARCH

Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

(2013) Yuan Huang et al.   CURRENT DRUG TARGETS

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

(2012) Rita Nahta et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors

(2012) A. Chakrabarty et al.   CANCER RESEARCH

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)

(2012) Cristina Oliveras-Ferraros et al.   CELL CYCLE

HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells

(2012) N. Duru et al.   CLINICAL CANCER RESEARCH

Artemin Stimulates Radio- and Chemo-resistance by Promoting TWIST1-BCL-2-dependent Cancer Stem Cell-like Behavior in Mammary Carcinoma Cells

(2012) Arindam Banerjee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Expression of Wnt3 Activates Wnt/ -Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells

(2012) Y. Wu et al.   MOLECULAR CANCER RESEARCH

HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter-Mediated Chemoresistance in Small Cell Lung Cancer

(2012) T. Minami et al.   MOLECULAR CANCER THERAPEUTICS

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population

(2012) Hasan Korkaya et al.   MOLECULAR CELL

ARTEMIN Promotes De Novo Angiogenesis in ER Negative Mammary Carcinoma through Activation of TWIST1-VEGF-A Signalling

(2012) Arindam Banerjee et al.   PLoS One

BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment

(2011) Jing-Yu Lang et al.   CANCER CELL

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors

(2011) Kareem Tawfik et al.   HUMAN PATHOLOGY

Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin

(2011) Maxim M. Bespalov et al.   JOURNAL OF CELL BIOLOGY

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

(2010) S-J Dawson et al.   BRITISH JOURNAL OF CANCER

Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

(2010) J Kang et al.   ONCOGENE

Stemming Resistance to HER-2 Targeted Therapy

(2009) Philippe L. Bedard et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Artemin is oncogenic for human mammary carcinoma cells

(2009) J Kang et al.   ONCOGENE

Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy

(2008) Qifeng Yang et al.   BREAST CANCER RESEARCH AND TREATMENT

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

(2008) D. L. Shattuck et al.   CANCER RESEARCH

Autocrine Human Growth Hormone Stimulates Oncogenicity of Endometrial Carcinoma Cells

(2008) Vijay Pandey et al.   ENDOCRINOLOGY

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

(2008) H Korkaya et al.   ONCOGENE

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY